Table 2.
Demographics and baseline characteristics (n = 42)
| Characteristic | n (%) |
|---|---|
| Age group | |
| 18 to <50 | 8 (19) |
| 50 to <65 | 22 (52.4) |
| ≥65 | 12 (28.6) |
| Gender | |
| Male | 33 (78.6) |
| Female | 9 (21.4) |
| Race | |
| White | 31 (73.8) |
| Black | 11 (26.2) |
| Tumor grade | |
| Unknown | 14 (33.3) |
| Well differentiated or G1 | 3 (7.1) |
| Moderately differentiated or G2 | 13 (31) |
| Poorly differentiated or undifferentiated or G3 | 4 (9.5) |
| Grade cannot be assessed or Gx | 8 (19) |
| BRAF | |
| Wild type | 13 (31) |
| Mutated | 0 |
| Unknown | 29 (69) |
| KRAS | |
| Wild type | 18 (42.9) |
| Mutated | 21 (50) |
| Unknown | 3 (7.1) |
| MSI | |
| Low | 1 (2.4) |
| Stable | 12 (28.6) |
| High | 0 |
| Unknown | 29 (69) |
| Number of lines of therapy prior to enrollment | |
| Median number of lines of therapy (min–max) | 3 (2–7) |
| <3 | 7 (16.7) |
| ≥3 | 35 (83.3) |
| Prior treatment with bevacizumab | |
| Yes | 34 (81) |
| No | 8 (19) |
| Prior treatment with capecitabine | |
| Yes | 17 (40.5) |
| No | 24 (57.1) |
| Unknown | 1 (2.4) |
| Prior treatment with cetuximab or panitumumab | |
| Yes | 18 (42.9) |
| No | 24 (57.1) |
Abbreviations: BRAF, B‐Raf; G1, grade 1; G2, grade 2; G3, grade 3; Gx, grade not assessed; KRAS, K‐ras; MSI, microsatellite instability.